Quantifying ERK activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling.

Sara J HamisYury KapelyukhAileen McLarenColin J HendersonC Roland WolfMark A J Chaplain

Published in: British journal of cancer (2021)

The model can be used to systematically motivate which dabrafenib-trametinib dose combinations, for treating BRAFV600E-mutated melanoma, warrant experimental investigation.

Keyphrases

pi k akt
signaling pathway
cell proliferation